Probucol Combined With Valsartan in Reducing Proteinuria in Diabetes Nephropathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00655330
Recruitment Status : Active, not recruiting
First Posted : April 9, 2008
Last Update Posted : August 24, 2016
Information provided by (Responsible Party):
Wei Shi, Guangdong General Hospital

Brief Summary:
This is a prospective randomized controlled, open-labeled study to identify the efficacy of probucol in combination with valsartan in patients with Diabetes nephropathy. The reduction of urinary albumin or proteinuria will be the primary outcome studied. The expected study duration will be 48 weeks.

Condition or disease Intervention/treatment
Type 2 Diabetes Mellitus Nephropathy Drug: Valsartan Drug: Placebo Drug: Probucol

Detailed Description:

a prospective randomized controlled, open-labeled study in patients with Diabetes nephropathy

  • Arm 1: Valsartan + Probucol Valsartan (160mg/day) + Probucol (750mg/day)
  • Arm 2: Valsartan + Placebo Valsartan (160mg/day) + Placebo

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 170 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Prospective Randomized, Controlled, Open-labeled Trial of Probucol Combined With Valsartan in Patients With Diabetes Nephropathy
Study Start Date : May 2008
Estimated Primary Completion Date : May 2017
Estimated Study Completion Date : May 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Kidney Diseases
Drug Information available for: Valsartan
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: 1
Valsartan (160mg/day)is given in combination with Placebo
Drug: Valsartan
Valsartan (160mg/day)
Drug: Placebo
Experimental: 2
Valsartan (160mg/day) + Probucol (750mg/day)
Drug: Valsartan
Valsartan (160mg/day)
Drug: Probucol
Probucol (750mg/day)

Primary Outcome Measures :
  1. urinary albumin excretion or proteinuria at week 48 [ Time Frame: 48 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   30 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Type 2 Diabetes nephropathy
  • Urinary albumin excretion 1-3g/24hours
  • Serum creatinine < 3mg/dl

Exclusion Criteria:

  • Type 1 diabetes mellitus
  • Renal diseases other than type 2 Diabetes nephropathy
  • Renal artery stenosis
  • Severe heart diseases
  • Tuberculosis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00655330

China, Guangdong
Guangdong General Hospital
Guangzhou, Guangdong, China, 510080
Sponsors and Collaborators
Guangdong General Hospital
Principal Investigator: Shi Wei, MD, PhD Nephrology Dept.,Guangdong General Hospital

Responsible Party: Wei Shi, Director of renal division of Guangdong General Hospital, Guangdong General Hospital Identifier: NCT00655330     History of Changes
Other Study ID Numbers: GPPH200603 -1
First Posted: April 9, 2008    Key Record Dates
Last Update Posted: August 24, 2016
Last Verified: August 2016

Keywords provided by Wei Shi, Guangdong General Hospital:
Type 2 diabetes mellitus

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Kidney Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Urologic Diseases
Urination Disorders
Urological Manifestations
Signs and Symptoms
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Anticholesteremic Agents
Hypolipidemic Agents
Lipid Regulating Agents
Protective Agents
Physiological Effects of Drugs